{"header":{"numFound":17328636,"maxScore":1.0,"queryTime":295,"page":1,"pageSize":10},"results":[{"authors":[{"id":null,"fullName":"Duran, I. (I.)","name":"I.","surname":"Duran","rank":1,"pid":null},{"id":null,"fullName":"Garzon, C. (C.)","name":"C.","surname":"Garzon","rank":2,"pid":null},{"id":null,"fullName":"Sanchez, A. (Andrés)","name":"A.","surname":"Sanchez","rank":3,"pid":null},{"id":null,"fullName":"Garcia-Carbonero, I. (I.)","name":"I.","surname":"Garcia-Carbonero","rank":4,"pid":null},{"id":null,"fullName":"Perez-Gracia, J.L. (Jose Luis)","name":"J. L.","surname":"Perez-Gracia","rank":5,"pid":null},{"id":null,"fullName":"Segui-Palmer, M.A. (M. A.)","name":"M. A.","surname":"Segui-Palmer","rank":6,"pid":null},{"id":null,"fullName":"Wei, R. (R.)","name":"R.","surname":"Wei","rank":7,"pid":null},{"id":null,"fullName":"Restovic, G. (G.)","name":"G.","surname":"Restovic","rank":8,"pid":null},{"id":null,"fullName":"Gasquet, J.A. (J. A.)","name":"J. A.","surname":"Gasquet","rank":9,"pid":null},{"id":null,"fullName":"Gutierrez, L. (L.)","name":"L.","surname":"Gutierrez","rank":10,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Costs study"},"provenance":null},{"subject":{"scheme":"keyword","value":"Bone metastases"},"provenance":null},{"subject":{"scheme":"keyword","value":"Health care resource utilisation"},"provenance":null},{"subject":{"scheme":"keyword","value":"Skeletal-related events"},"provenance":null}],"mainTitle":"Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours","subTitle":null,"descriptions":["To estimate the cost per skeletal-related event (SRE) in patients with bone metastases secondary to solid tumours in the Spanish healthcare setting. METHODS: Patients diagnosed with bone metastases secondary to breast, prostate or lung cancer were included in this multicentre, observational study. SREs are defined as pathologic fracture (vertebral and non-vertebral fracture), radiation to bone, spinal cord compression or surgery to bone. Health resource utilisation associated with these events (inpatient stays, outpatient, emergency room and home health visits, nursing home stays and procedures) were collected retrospectively for all SREs that occurred in the 97 days prior to enrolment and prospectively during follow-up. Unit costs were obtained from the 2010 eSalud healthcare costs database. RESULTS: A total of 93 Spanish patients with solid tumours were included (31 had breast cancer, 21 prostate cancer and 41 lung cancer), contributing a total of 143 SREs to this cost analysis. Inpatient stays (between 9.0 and 29.9 days of mean length of stay per inpatient stay by SRE type) and outpatient visits (between 1.7 and 6.4 mean visits per SRE type) were the most frequently reported types of health resources utilised. The mean cost per SRE was between <euro>2,377.79 (radiation to bone) and <euro>7,902.62 (spinal cord compression). CONCLUSION: SREs are associated with a significant consumption of healthcare resources that generate a substantial economic burden for the Spanish healthcare system."],"publicationDate":"2013-01-01","publisher":"Springer","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::00207214a5a0f2b03a42ee291345df09","originalIds":["oai:navarra.escire.net:10171/36152","50|00064aabbda9::00207214a5a0f2b03a42ee291345df09"],"pids":[{"scheme":"handle","value":"10171/36152"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":5.0245597E-10,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":[{"code":"cancer-research","label":"Cancer Research","provenance":null}],"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/36152"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/36152"],"publicationDate":"2013-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Morell-Azanza, L. (Lydia)","name":"L.","surname":"Morell-Azanza","rank":1,"pid":null},{"id":null,"fullName":"Ojeda-Rodríguez, A. (Ana)","name":"A.","surname":"Ojeda-Rodríguez","rank":2,"pid":null},{"id":null,"fullName":"Ochotorena-Elicegui, A. (Amaia)","name":"A.","surname":"Ochotorena-Elicegui","rank":3,"pid":null},{"id":null,"fullName":"Martin-Calvo, N. (Nerea)","name":"N.","surname":"Martin-Calvo","rank":4,"pid":null},{"id":null,"fullName":"Chueca, M. (María)","name":"M.","surname":"Chueca","rank":5,"pid":null},{"id":null,"fullName":"Marti-del-Moral, A. (Amelia)","name":"A.","surname":"Marti-Del-Moral","rank":6,"pid":null},{"id":null,"fullName":"Azcona-San-Julian, M.C. (María Cristina)","name":"M. C.","surname":"Azcona-San-Julian","rank":7,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Accelerometer"},"provenance":null},{"subject":{"scheme":"keyword","value":"Leptin"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"MVPA"},"provenance":null},{"subject":{"scheme":"keyword","value":"Materias Investigacion::Ciencias de la Salud::Nutrición y dietética"},"provenance":null},{"subject":{"scheme":"keyword","value":"Obesity children"},"provenance":null},{"subject":{"scheme":"keyword","value":"Metabolic risk"},"provenance":null}],"mainTitle":"Changes in objectively measured physical activity after a multidisciplinary lifestyle intervention in children with abdominal obesity: a randomized control trial","subTitle":null,"descriptions":["Background: Physical activity (PA) is associated with changes in body composition that affect insulin sensitivity and leptin levels. Few studies have assessed the effect of lifestyle interventions on changes in objectively measured PA levels in obese children. To evaluate the effects of a multidisciplinary lifestyle intervention on anthropometric indices, biochemical parameters and accelerometer measured PA in abdominal obese children. Methods: A randomized control trial was performed in 106 children and adolescents with abdominal obesity. Participants were randomly assigned to usual or intensive care group for 8-week. PA was measured by accelerometry over four days including, at least, two weekdays in all participants. Both groups were encouraged to accumulate an extra time of 200 min per week in their PA. Results: At baseline, 75% of subjects do not fulfill the WHO recommendation of being more than 60 min/day on moderate-to-vigorous PA (MVPA). The intensive care group achieved a significant reduction in anthropometric indexes compared to the usual care but no significant change was found in biochemical or PA parameters. Both groups achieved a significant reduction in light PA. Interestingly, intensive care participants significantly increased MVPA in 5.5 min/day. Moreover, an inverse association between changes in MVPA and leptin levels was found. Conclusion: The two lifestyle intervention reduced anthropometric indexes and lowered light PA in abdominal obese children. No significant differences were observed between intensive care and usual care in regard to PA. Intensive care participants significantly increase physical activity (MVPA) and, changes in MVPA were inversely associated with changes in leptin levels after the intervention."],"publicationDate":"2019-01-01","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::00ad0f93d4738639fcdbc7a4297a8297","originalIds":["oai:navarra.escire.net:10171/61974","50|00064aabbda9::00ad0f93d4738639fcdbc7a4297a8297"],"pids":[{"scheme":"handle","value":"10171/61974"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":1.0119146E-9,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":null,"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/61974"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/61974"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Pato, E. (Esperanza)","name":"E.","surname":"Pato","rank":1,"pid":null},{"id":null,"fullName":"Martín‐Martínez, M. A. (María Auxiliadora)","name":"M. A.","surname":"Martín‐martínez","rank":2,"pid":null},{"id":null,"fullName":"Castelló, A. (Adela)","name":"A.","surname":"Castelló","rank":3,"pid":null},{"id":null,"fullName":"Méndez‐Fernández, R. (Rosalía)","name":"R.","surname":"Méndez‐fernández","rank":4,"pid":null},{"id":null,"fullName":"Muñoz-Fernández, S. (Santiago)","name":"S.","surname":"Muñoz-Fernández","rank":5,"pid":null},{"id":null,"fullName":"Cordero-Coma, M. (Miguel)","name":"M.","surname":"Cordero-Coma","rank":6,"pid":null},{"id":null,"fullName":"Martínez-Costa, L. (Lucía)","name":"L.","surname":"Martínez-Costa","rank":7,"pid":null},{"id":null,"fullName":"Valls, E. (Elia)","name":"E.","surname":"Valls","rank":8,"pid":null},{"id":null,"fullName":"Reyes, M. (Miguel)","name":"M.","surname":"Reyes","rank":9,"pid":null},{"id":null,"fullName":"Francisco, F. (Félix)","name":"F.","surname":"Francisco","rank":10,"pid":null},{"id":null,"fullName":"Esteban, M. (Mar)","name":"M.","surname":"Esteban","rank":11,"pid":null},{"id":null,"fullName":"Fonollosa, A. (Alex)","name":"A.","surname":"Fonollosa","rank":12,"pid":null},{"id":null,"fullName":"Sánchez-Alonso, F. (Fernando)","name":"F.","surname":"Sánchez-Alonso","rank":13,"pid":null},{"id":null,"fullName":"Fernández-Espartero, C. (Cruz)","name":"C.","surname":"Fernández-Espartero","rank":14,"pid":null},{"id":null,"fullName":"Díaz-Valle, T. (Teresa)","name":"T.","surname":"Díaz-Valle","rank":15,"pid":null},{"id":null,"fullName":"Carrasco-Gimeno, J.M. (José Miguel)","name":"J. M.","surname":"Carrasco-Gimeno","rank":16,"pid":null},{"id":null,"fullName":"Beltrán-Catalán, E. (Emma)","name":"E.","surname":"Beltrán-Catalán","rank":17,"pid":null},{"id":null,"fullName":"Hernández-Garfella, M. (Marisa)","name":"M.","surname":"Hernández-Garfella","rank":18,"pid":null},{"id":null,"fullName":"Hernández, M.V. (María Victoria)","name":"M. V.","surname":"Hernández","rank":19,"pid":null},{"id":null,"fullName":"Pelegrín, L. (Laura)","name":"L.","surname":"Pelegrín","rank":20,"pid":null},{"id":null,"fullName":"Blanco, R. (Ricardo)","name":"R.","surname":"Blanco","rank":21,"pid":null},{"id":null,"fullName":"Díaz-Valle, D. (David)","name":"D.","surname":"Díaz-Valle","rank":22,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Uveitis"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Ocular inflammation"},"provenance":null},{"subject":{"scheme":"keyword","value":"Activity index"},"provenance":null},{"subject":{"scheme":"keyword","value":"Outcome measures"},"provenance":null}],"mainTitle":"Development of an activity disease score in patients with uveitis (UVEDAI)","subTitle":null,"descriptions":["To develop a disease activity index for patients with uveitis (UVEDAI) encompassing the relevant domains of disease activity considered important among experts in this field. The steps for designing UVEDAI were: (a) Defining the construct and establishing the domains through a formal judgment of experts, (b) A two-round Delphi study with a panel of 15 experts to determine the relevant items, (c) Selection of items: A logistic regression model was developed that set ocular inflammatory activity as the dependent variable. The construct \"uveitis inflammatory activity\" was defined as any intraocular inflammation that included external structures (cornea) in addition to uvea. Seven domains and 15 items were identified: best-corrected visual acuity, inflammation of the anterior chamber (anterior chamber cells, hypopyon, the presence of fibrin, active posterior keratic precipitates and iris nodules), intraocular pressure, inflammation of the vitreous cavity (vitreous haze, snowballs and snowbanks), central macular edema, inflammation of the posterior pole (the presence and number of choroidal/retinal lesions, vascular inflammation and papillitis), and global assessment from both (patient and physician). From all the variables studied in the multivariate model, anterior chamber cell grade, vitreous haze, central macular edema, inflammatory vessel sheathing, papillitis, choroidal/retinal lesions and patient evaluation were included in UVEDAI. UVEDAI is an index designed to assess the global ocular inflammatory activity in patients with uveitis. It might prove worthwhile to motorize the activity of this extraarticular manifestation of some rheumatic diseases."],"publicationDate":"2017-01-01","publisher":"Springer Verlag","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::00c2ebbb0b9881b740370609d69351cf","originalIds":["50|00064aabbda9::00c2ebbb0b9881b740370609d69351cf","oai:navarra.escire.net:10171/48901"],"pids":[{"scheme":"handle","value":"10171/48901"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":7.8583434E-10,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":null,"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/48901"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/48901"],"publicationDate":"2017-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Gil-Alana, L.A. (Luis A.)","name":"L. A.","surname":"Gil-Alana","rank":1,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0502 economics and business"},"provenance":null},{"subject":{"scheme":"FOS","value":"05 social sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Materias Investigacion::Economía y Empresa"},"provenance":null}],"mainTitle":"Time series modelling of sunspot numbers using long range cyclical dependence.","subTitle":null,"descriptions":null,"publicationDate":"2009-01-01","publisher":"Springer","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::0139b445f6cb1da26b43d963b31aa637","originalIds":["oai:navarra.escire.net:10171/7148","50|00064aabbda9::0139b445f6cb1da26b43d963b31aa637"],"pids":[{"scheme":"handle","value":"10171/7148"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":3.5303266E-10,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":null,"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/7148"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/7148"],"publicationDate":"2009-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Arredondo-Montero, J. (Javier)","name":"J.","surname":"Arredondo-Montero","rank":1,"pid":null},{"id":null,"fullName":"Antona, G. (Giuseppa)","name":"G.","surname":"Antona","rank":2,"pid":null},{"id":null,"fullName":"Rivero-Marcotegui, A. (Adriana)","name":"A.","surname":"Rivero-Marcotegui","rank":3,"pid":null},{"id":null,"fullName":"Bardají-Pascual, C. (Carlos)","name":"C.","surname":"Bardají-Pascual","rank":4,"pid":null},{"id":null,"fullName":"Bronte-Anaut, M. (Mónica)","name":"M.","surname":"Bronte-Anaut","rank":5,"pid":null},{"id":null,"fullName":"Ros-Briones, R. (Raquel)","name":"R.","surname":"Ros-Briones","rank":6,"pid":null},{"id":null,"fullName":"Fernández-Celís, A. (Amaya)","name":"A.","surname":"Fernández-Celís","rank":7,"pid":null},{"id":null,"fullName":"Lopez-Andres, N. (Natalia)","name":"N.","surname":"Lopez-Andres","rank":8,"pid":null},{"id":null,"fullName":"Martin-Calvo, N. (Nerea)","name":"N.","surname":"Martin-Calvo","rank":9,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Pediatric"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Interleukin-6"},"provenance":null},{"subject":{"scheme":"keyword","value":"Uncomplicated"},"provenance":null},{"subject":{"scheme":"keyword","value":"Diagnostic"},"provenance":null},{"subject":{"scheme":"keyword","value":"Acute"},"provenance":null},{"subject":{"scheme":"keyword","value":"Appendicitis"},"provenance":null},{"subject":{"scheme":"keyword","value":"Complicated"},"provenance":null}],"mainTitle":"Discriminatory capacity of serum interleukin-6 between complicated and uncomplicated acute appendicitis in children: a prospective validation study","subTitle":null,"descriptions":["Background: Serum interleukin-6 (IL-6) has a moderate diagnostic performance in pediatric acute appendicitis (PAA). The evidence regarding its capacity to discern between complicated and uncomplicated PAA is scarce. Methods: We designed a prospective observational study to validate serum IL-6 as a marker for diagnostic classification between complicated and uncomplicated PAA. This study included 205 patients divided into three groups: (1) patients who underwent major outpatient surgery (n = 57); (2) patients with non-surgical abdominal pain (NSAP) in whom the diagnosis of PAA was excluded (n = 53), and (3) patients with a confirmed diagnosis of PAA (n = 95). The PAA patients were further classified as uncomplicated or complicated PAA. IL-6 concentration was determined in all patients at diagnosis. Comparative statistical analysis was performed using the Mann-Whitney U test, the Fisher exact test and the Kruskall Wallis test. The area under the receiver operating characteristic curves (AUC) were calculated. Results: Median (interquartile range, IQR) serum IL-6 values were 2 pg/mL (2.0-3.4) in group 1, 3.9 pg/mL (2.4-11.9) in group 2, and 23.9 pg/mL (11.1-61.0) in group 3 (P < 0.001). Among the participants in group 3, those with uncomplicated PAA had median (IQR) serum IL-6 values of 17.2 pg/mL (8.5-36.8), and those with complicated PAA had 60.25 pg/mL (27.1-169) serum IL-6 (P < 0.001). At the cut-off point of 19.55 pg/mL, the AUC for the discrimination between patients in group 2 vs. 3 was 0.83 [95% confidence interval (CI) 0.76-0.90], with a sensitivity of 61.3% and a specificity of 86.8. The AUC for the discrimination between patients with uncomplicated and complicated PAA was 0.77 (95% CI 0.68-0.86) and the cut-off point was 25.90 pg/mL, with a sensitivity and specificity of 84.6% and 65.6%, respectively. Conclusions: Serum IL-6 has a good performance in discerning between complicated and uncomplicated PAA. A score including clinical and radiological variables may increase the diagnostic performance of this molecule."],"publicationDate":"2022-01-01","publisher":"Springer","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::014878e89530f5cb39830fc96700ffed","originalIds":["50|00064aabbda9::014878e89530f5cb39830fc96700ffed","oai:navarra.escire.net:10171/65743"],"pids":[{"scheme":"handle","value":"10171/65743"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":1.5205207E-9,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":null,"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/65743"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/65743"],"publicationDate":"2022-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Cattral, J.W.S. (J. W. S.)","name":"J. W. S.","surname":"Cattral","rank":1,"pid":null},{"id":null,"fullName":"Asin, E. (E.)","name":"E.","surname":"Asin","rank":2,"pid":null},{"id":null,"fullName":"Freeman, J. (J.)","name":"J.","surname":"Freeman","rank":3,"pid":null},{"id":null,"fullName":"Troconiz, I.F. (Iñaki F.)","name":"I. F.","surname":"Troconiz","rank":4,"pid":null},{"id":null,"fullName":"Kirby, A. (A.)","name":"A.","surname":"Kirby","rank":5,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacodynamics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-bacterial agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Administration, oral"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Modelling"},"provenance":null},{"subject":{"scheme":"keyword","value":"Simulation"},"provenance":null}],"mainTitle":"A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis","subTitle":null,"descriptions":["Antibiotic resistance to oral antibiotics recommended for pyelonephritis is increasing. The objective was to determine if there is a pharmacological basis to consider alternative treatments/novel dosing regimens for the oral treatment of pyelonephritis. A systematic review identified pharmacokinetic models of suitable quality for a selection of antibiotics with activity against Escherichia coli. MIC data was obtained for a population of E. coli isolates derived from patients with pyelonephritis. Pharmacokinetic/pharmacodynamic (PK/PD) simulations determined probability of target attainment (PTA) and cumulative fraction response (CFR) values for sub-populations of the E. coli population at varying doses. There are limited high-quality models available for the agents investigated. Pharmacokinetic models of sufficient quality for simulation were identified for amoxicillin, amoxicillin-clavulanic acid, cephalexin, ciprofloxacin, and fosfomycin trometamol. These antibiotics were predicted to have PTAs ≥ 0.85 at or below standard doses for the tested E. coli population including cephalexin 1500 mg 8 hourly for 22% of the population (MIC ≤ 4 mg/L) and ciprofloxacin 100 mg 12 hourly for 71% of the population (MIC ≤ 0.06 mg/L). For EUCAST-susceptible E. coli isolates, doses achieving CFRs ≥ 0.9 included amoxicillin 2500 mg 8 hourly, cephalexin 4000 mg 6 hourly, ciprofloxacin 200 mg 12 hourly, and 3000 mg of fosfomycin 24 hourly. Limitations in the PK data support carrying out additional PK studies in populations of interest. Oral antibiotics including amoxicillin, amoxicillin-clavulanic acid, and cephalexin have potential to be effective for a proportion of patients with pyelonephritis. Ciprofloxacin may be effective at lower doses than currently prescribed."],"publicationDate":"2019-01-01","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::0530e6683d949521aeb6c2d47e31da12","originalIds":["50|00064aabbda9::0530e6683d949521aeb6c2d47e31da12","oai:navarra.escire.net:10171/63626"],"pids":[{"scheme":"handle","value":"10171/63626"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":1.0119146E-9,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":null,"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/63626"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/63626"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Grávalos, C. (C.)","name":"C.","surname":"Grávalos","rank":1,"pid":null},{"id":null,"fullName":"Sanmartin-Jiménez, O. (Onofre)","name":"O.","surname":"Sanmartin-Jiménez","rank":2,"pid":null},{"id":null,"fullName":"Gurpide, A. (Alfonso)","name":"A.","surname":"Gurpide","rank":3,"pid":null},{"id":null,"fullName":"España, A. (Agustín)","name":"A.","surname":"España","rank":4,"pid":null},{"id":null,"fullName":"Majem-Tarruella, M. (Margarita)","name":"M.","surname":"Majem-Tarruella","rank":5,"pid":null},{"id":null,"fullName":"Suh-Oh, H.J. (H. J.)","name":"H. J.","surname":"Suh-Oh","rank":6,"pid":null},{"id":null,"fullName":"Aragón, I. (I.)","name":"I.","surname":"Aragón","rank":7,"pid":null},{"id":null,"fullName":"Segura, S. (S.)","name":"S.","surname":"Segura","rank":8,"pid":null},{"id":null,"fullName":"Beato, C. (C.)","name":"C.","surname":"Beato","rank":9,"pid":null},{"id":null,"fullName":"Botella-Estrada, R. (Rafael)","name":"R.","surname":"Botella-Estrada","rank":10,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Antiangiogenic drugs"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Immune checkpoint inhibitors"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Targeted therapies"},"provenance":null},{"subject":{"scheme":"keyword","value":"Dermatological toxicity"},"provenance":null},{"subject":{"scheme":"keyword","value":"MTOR inhibitors"},"provenance":null},{"subject":{"scheme":"keyword","value":"Materias Investigacion::Ciencias de la Salud::Oncología"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-EGFR"},"provenance":null}],"mainTitle":"Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology","subTitle":null,"descriptions":["Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management."],"publicationDate":"2019-01-01","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::05b572206d4ca64a9f913ab9a83953aa","originalIds":["50|00064aabbda9::05b572206d4ca64a9f913ab9a83953aa","oai:navarra.escire.net:10171/62024"],"pids":[{"scheme":"handle","value":"10171/62024"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":1.0119146E-9,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":[{"code":"cancer-research","label":"Cancer Research","provenance":null}],"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/62024"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/62024"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Klompmaker, S. (Sjors)","name":"S.","surname":"Klompmaker","rank":1,"pid":null},{"id":null,"fullName":"Hilst, J. (Jony) van","name":"J.","surname":"Hilst","rank":2,"pid":null},{"id":null,"fullName":"Gerritsen, S. (Sarah L.)","name":"S.","surname":"Gerritsen","rank":3,"pid":null},{"id":null,"fullName":"Adham, M. (Mustapha)","name":"M.","surname":"Adham","rank":4,"pid":null},{"id":null,"fullName":"Albiol-Quer, T. (Teresa)","name":"T.","surname":"Albiol-Quer","rank":5,"pid":null},{"id":null,"fullName":"Bassi, C. (Claudio)","name":"C.","surname":"Bassi","rank":6,"pid":null},{"id":null,"fullName":"Berrevoet, F. (Frederik)","name":"F.","surname":"Berrevoet","rank":7,"pid":null},{"id":null,"fullName":"Boggi, U. (Ugo)","name":"U.","surname":"Boggi","rank":8,"pid":null},{"id":null,"fullName":"Busch, O. (Olivier R.)","name":"O.","surname":"Busch","rank":9,"pid":null},{"id":null,"fullName":"Cesaretti, M. (Manuela)","name":"M.","surname":"Cesaretti","rank":10,"pid":null},{"id":null,"fullName":"Dalla-Valle, R. (Raffaele)","name":"R.","surname":"Dalla-Valle","rank":11,"pid":null},{"id":null,"fullName":"Darnis, B. (Benjamin)","name":"B.","surname":"Darnis","rank":12,"pid":null},{"id":null,"fullName":"De-Pastena, M. (Matteo)","name":"M.","surname":"De-Pastena","rank":13,"pid":null},{"id":null,"fullName":"Del-Chiaro, M. (Marco)","name":"M.","surname":"Del-Chiaro","rank":14,"pid":null},{"id":null,"fullName":"Grützmann, R. (Robert)","name":"R.","surname":"Grützmann","rank":15,"pid":null},{"id":null,"fullName":"Diener, M.K. (Markus K.)","name":"M. K.","surname":"Diener","rank":16,"pid":null},{"id":null,"fullName":"Dumitrascu, T. (Traian)","name":"T.","surname":"Dumitrascu","rank":17,"pid":null},{"id":null,"fullName":"Friess, H. (Helmut)","name":"H.","surname":"Friess","rank":18,"pid":null},{"id":null,"fullName":"Ivanecz, A. (Arpad)","name":"A.","surname":"Ivanecz","rank":19,"pid":null},{"id":null,"fullName":"Karayiannakis, A. (Anastasios)","name":"A.","surname":"Karayiannakis","rank":20,"pid":null},{"id":null,"fullName":"Fusai, G.K. (Giuseppe K.)","name":"G. K.","surname":"Fusai","rank":21,"pid":null},{"id":null,"fullName":"Labori, K.J. (Knut J.)","name":"K. J.","surname":"Labori","rank":22,"pid":null},{"id":null,"fullName":"Lombardo, C. (Carlo)","name":"C.","surname":"Lombardo","rank":23,"pid":null},{"id":null,"fullName":"López-Ben, S. (Santiago)","name":"S.","surname":"López-Ben","rank":24,"pid":null},{"id":null,"fullName":"Mabrut, J.Y. (Jean-Yves)","name":"J. Y.","surname":"Mabrut","rank":25,"pid":null},{"id":null,"fullName":"Niesen, W. (Willem)","name":"W.","surname":"Niesen","rank":26,"pid":null},{"id":null,"fullName":"Pardo, F. (Fernando)","name":"F.","surname":"Pardo","rank":27,"pid":null},{"id":null,"fullName":"Perinel, J. (Julie)","name":"J.","surname":"Perinel","rank":28,"pid":null},{"id":null,"fullName":"Popescu, I. (Irinel)","name":"I.","surname":"Popescu","rank":29,"pid":null},{"id":null,"fullName":"Roeyen, G. (Geert)","name":"G.","surname":"Roeyen","rank":30,"pid":null},{"id":null,"fullName":"Sauvanet, A. (Alain)","name":"A.","surname":"Sauvanet","rank":31,"pid":null},{"id":null,"fullName":"Prasad, R. (Raj)","name":"R.","surname":"Prasad","rank":32,"pid":null},{"id":null,"fullName":"Sturesson, C. (Christian)","name":"C.","surname":"Sturesson","rank":33,"pid":null},{"id":null,"fullName":"Lesurtel, M. (Mickael)","name":"M.","surname":"Lesurtel","rank":34,"pid":null},{"id":null,"fullName":"Kleeff, J. (Jorg)","name":"J.","surname":"Kleeff","rank":35,"pid":null},{"id":null,"fullName":"Salvia, R. (Roberto)","name":"R.","surname":"Salvia","rank":36,"pid":null},{"id":null,"fullName":"Besselink, M.G. (Marc G.)","name":"M. G.","surname":"Besselink","rank":37,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Celiac axis resection"},"provenance":null},{"subject":{"scheme":"keyword","value":"Appleby procedure"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pancreatic cancer"},"provenance":null},{"subject":{"scheme":"keyword","value":"Western multicenter studies"},"provenance":null}],"mainTitle":"Outcomes after distal pancreatectomy with celiac axis resection for pancreatic cancer: a Pan-European retrospective cohort study","subTitle":null,"descriptions":["Background: Western multicenter studies on distal pancreatectomy with celiac axis resection (DP-CAR), also known as the Appleby procedure, for locally advanced pancreatic cancer are lacking. We aimed to study overall survival, morbidity, mortality and the impact of preoperative hepatic artery embolization (PHAE). Methods: Retrospective cohort study within the European-African Hepato-Pancreato-Biliary-Association, on DP-CAR between 1-1-2000 and 6-1-2016. Primary endpoint was overall survival. Secondary endpoints were radicality (R0-resection), 90-day mortality, major morbidity, and pancreatic fistulae (grade B/C). Results: We included 68 patients from 20 hospitals in 12 countries. Postoperatively, 53% of patients had R0-resection, 25% major morbidity, 21% an ISGPS grade B/C pancreatic fistula, and 16% mortality. In total, 82% received (neo-)adjuvant chemotherapy and median overall survival in 62 patients with pancreatic ductal adenocarcinoma patients was 18 months (CI 10-37). We observed no impact of PHAE on ischemic complications. Conclusions: DP-CAR combined with chemotherapy for locally advanced pancreatic cancer is associated with acceptable overall survival. The 90-day mortality is too high and should be reduced. Future studies should investigate to what extent increasing surgical volume or better patient selection can improve outcomes."],"publicationDate":"2018-01-01","publisher":"Springer Science","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::06852ecdb5bb78b3a36094e49c6c1a3d","originalIds":["50|00064aabbda9::06852ecdb5bb78b3a36094e49c6c1a3d","oai:navarra.escire.net:10171/65535"],"pids":[{"scheme":"handle","value":"10171/65535"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":8.8985047E-10,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":[{"code":"cancer-research","label":"Cancer Research","provenance":null}],"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/65535"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/65535"],"publicationDate":"2018-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Santaballa, A. (Ana)","name":"A.","surname":"Santaballa","rank":1,"pid":null},{"id":null,"fullName":"Matías-Guiu, X. (Xavier)","name":"X.","surname":"Matías-Guiu","rank":2,"pid":null},{"id":null,"fullName":"Redondo, A. M. (Alba M.)","name":"A. M.","surname":"Redondo","rank":3,"pid":null},{"id":null,"fullName":"Carballo, N. (N.)","name":"N.","surname":"Carballo","rank":4,"pid":null},{"id":null,"fullName":"Gil, M. (Miguel)","name":"M.","surname":"Gil","rank":5,"pid":null},{"id":null,"fullName":"Gomez, C. (C.)","name":"C.","surname":"Gomez","rank":6,"pid":null},{"id":null,"fullName":"Gorostidi, M. (M)","name":"M.","surname":"Gorostidi","rank":7,"pid":null},{"id":null,"fullName":"Gutierrez, M. (M.)","name":"M.","surname":"Gutierrez","rank":8,"pid":null},{"id":null,"fullName":"González-Martín, A. (Adrián)","name":"A.","surname":"González-Martín","rank":9,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Endometrial cancer"},"provenance":null},{"subject":{"scheme":"keyword","value":"Radiotherapy"},"provenance":null},{"subject":{"scheme":"keyword","value":"Chemotherapy"},"provenance":null},{"subject":{"scheme":"keyword","value":"Adjuvant treatment"},"provenance":null}],"mainTitle":"SEOM clinical guidelines for endometrial cancer (2017)","subTitle":null,"descriptions":["Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defned and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies."],"publicationDate":"2018-01-01","publisher":"Springer","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::06c79fa45af55650b6b27f565f5b297f","originalIds":["oai:navarra.escire.net:10171/65692","50|00064aabbda9::06c79fa45af55650b6b27f565f5b297f"],"pids":[{"scheme":"handle","value":"10171/65692"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":8.8985047E-10,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":[{"code":"cancer-research","label":"Cancer Research","provenance":null}],"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/65692"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/65692"],"publicationDate":"2018-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null},{"authors":[{"id":null,"fullName":"Mendichovszky, I.A. (Iosif A.)","name":"I. A.","surname":"Mendichovszky","rank":1,"pid":null},{"id":null,"fullName":"Pullens, P. (Pim)","name":"P.","surname":"Pullens","rank":2,"pid":null},{"id":null,"fullName":"Dekkers, I. (Ilona)","name":"I.","surname":"Dekkers","rank":3,"pid":null},{"id":null,"fullName":"Nery, F. (Fabio)","name":"F.","surname":"Nery","rank":4,"pid":null},{"id":null,"fullName":"Bane, O. (Octavia)","name":"O.","surname":"Bane","rank":5,"pid":null},{"id":null,"fullName":"Pohlmann, A. (Andreas)","name":"A.","surname":"Pohlmann","rank":6,"pid":null},{"id":null,"fullName":"Boer, A. (Anneloes) de","name":"A.","surname":"Boer","rank":7,"pid":null},{"id":null,"fullName":"Ljimani, A. (Alexandra)","name":"A.","surname":"Ljimani","rank":8,"pid":null},{"id":null,"fullName":"Odudu, A. (Aghogho)","name":"A.","surname":"Odudu","rank":9,"pid":null},{"id":null,"fullName":"Buchanan, C.E. (Charlotte E.)","name":"C. E.","surname":"Buchanan","rank":10,"pid":null},{"id":null,"fullName":"Sharma, K. (Kanishka)","name":"K.","surname":"Sharma","rank":11,"pid":null},{"id":null,"fullName":"Laustsen, C. (Christoffer)","name":"C.","surname":"Laustsen","rank":12,"pid":null},{"id":null,"fullName":"Harteveld, A.A. (Anita A.)","name":"A. A.","surname":"Harteveld","rank":13,"pid":null},{"id":null,"fullName":"Golay, X. (Xavier)","name":"X.","surname":"Golay","rank":14,"pid":null},{"id":null,"fullName":"Pedrosa, I. (Ivan)","name":"I.","surname":"Pedrosa","rank":15,"pid":null},{"id":null,"fullName":"Alsop, D.C. (David C.)","name":"D. C.","surname":"Alsop","rank":16,"pid":null},{"id":null,"fullName":"Fain, S.B. (Sean B.)","name":"S. B.","surname":"Fain","rank":17,"pid":null},{"id":null,"fullName":"Caroli, A. (Anna)","name":"A.","surname":"Caroli","rank":18,"pid":null},{"id":null,"fullName":"Prasad, P.V. (Pottumarthi V.)","name":"P. V.","surname":"Prasad","rank":19,"pid":null},{"id":null,"fullName":"Francis, S.T. (Susan T.)","name":"S. T.","surname":"Francis","rank":20,"pid":null},{"id":null,"fullName":"Sigmund, E. (Eric)","name":"E.","surname":"Sigmund","rank":21,"pid":null},{"id":null,"fullName":"Fernández-Seara, M.A. (María A.)","name":"M. A.","surname":"Fernández-Seara","rank":22,"pid":null},{"id":null,"fullName":"Sourbron, S. (Steven)","name":"S.","surname":"Sourbron","rank":23,"pid":null}],"openAccessColor":null,"publiclyFunded":null,"eoscIfGuidelines":null,"type":"other","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Consensus"},"provenance":null},{"subject":{"scheme":"keyword","value":"Standardisation"},"provenance":null},{"subject":{"scheme":"keyword","value":"Kidney"},"provenance":null},{"subject":{"scheme":"keyword","value":"Biomarkers"},"provenance":null},{"subject":{"scheme":"keyword","value":"Imaging"},"provenance":null}],"mainTitle":"Technical recommendations for clinical translation of renal MRI: a consensus project of the Cooperation in Science and Technology Action PARENCHIMA","subTitle":null,"descriptions":["Purpose The potential of renal MRI biomarkers has been increasingly recognised, but clinical translation requires more standardisation. The PARENCHIMA consensus project aims to develop and apply a process for generating technical recommendations on renal MRI. Methods A task force was formed in July 2018 focused on fve methods. A draft process for attaining consensus was distributed publicly for consultation and fnalised at an open meeting (Prague, October 2018). Four expert panels completed surveys between October 2018 and March 2019, discussed results and refned the surveys at a face-to-face meeting (Aarhus, March 2019) and completed a second round (May 2019). Results A seven-stage process was defned: (1) formation of expert panels; (2) defnition of the context of use; (3) literature review; (4) collection and comparison of MRI protocols; (5) consensus generation by an approximate Delphi method; (6) reporting of results in vendor-neutral and vendor-specifc terms; (7) ongoing review and updating. Application of the process resulted in 166 consensus statements. Conclusion The process generated meaningful technical recommendations across very diferent MRI methods, while allowing for improvement and refnement as open issues are resolved. The results are likely to be widely supported by the renal MRI community and thereby promote more harmonisation."],"publicationDate":"2020-01-01","publisher":"Springer","embargoEndDate":null,"sources":null,"formats":["application/pdf"],"contributors":["Repositorio de la Universidad de Navarra"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":null,"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"00064aabbda9::072ad64a3ab8ba9171356de0d6586a3d","originalIds":["oai:navarra.escire.net:10171/67923","50|00064aabbda9::072ad64a3ab8ba9171356de0d6586a3d"],"pids":[{"scheme":"handle","value":"10171/67923"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":0.0,"influence":2.2251732E-9,"popularity":1.1551581E-9,"impulse":0.0,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"projects":null,"organizations":null,"communities":null,"collectedFrom":[{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}],"instances":[{"pids":[{"scheme":"handle","value":"10171/67923"}],"accessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/","openAccessRoute":null},"type":"Other ORP type","urls":["https://hdl.handle.net/10171/67923"],"publicationDate":"2020-01-01","refereed":"nonPeerReviewed","hostedBy":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"},"collectedFrom":{"key":"openaire____::891381590337449b8dfd6259d4031ae1","value":"NAVARA SCIRE"}}],"links":null,"otherTitles":null,"inDiamondJournal":null,"green":null,"isGreen":null,"isInDiamondJournal":null}]}